Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
NOVEL FORMULATION OF CT-P13 (Infliximab biosimilar) FOR SUBCUTANEOUS ADMINISTRATION: 30 WEEK RESULTS FROM A PART 2 of PHASE I/III RANDOMISED CONTROLLED TRIAL IN PATIENTS WITH RHEUMATOID ARTHRITIS.
- Authors
- 유대현
- Issue Date
- 15-Jun-2019
- Place
- Madrid, Spain
- Conference Name
- EULAR 2018
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 2. Conference Papers
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.